Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$4.2 million.

  • Ascendis Pharma A's Tax Provisions fell 27748.02% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.9 million, marking a year-over-year decrease of 520.8%. This contributed to the annual value of -$5.2 million for FY2024, which is 16670.96% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Tax Provisions is -$4.2 million, which was down 27748.02% from -$4.4 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Tax Provisions peaked at $1.4 million during Q1 2023, and registered a low of -$6.2 million during Q4 2023.
  • In the last 5 years, Ascendis Pharma A's Tax Provisions had a median value of -$246607.3 in 2024 and averaged -$1.3 million.
  • Data for Ascendis Pharma A's Tax Provisions shows a peak YoY increase of 227971.14% (in 2022) and a maximum YoY decrease of 408385.81% (in 2022) over the last 5 years.
  • Ascendis Pharma A's Tax Provisions (Quarter) stood at -$130412.7 in 2021, then plummeted by 4083.86% to -$5.5 million in 2022, then fell by 14.19% to -$6.2 million in 2023, then surged by 81.39% to -$1.2 million in 2024, then tumbled by 264.7% to -$4.2 million in 2025.
  • Its Tax Provisions was -$4.2 million in Q3 2025, compared to -$4.4 million in Q2 2025 and -$1.1 million in Q1 2025.